Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03762473 · ClinicalTrials.gov registry record · Phase 2
Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
NCT03762473 is a Phase 2 study that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 89 participants.
The verdict
NCT03762473, a Phase 2 study, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
Study Summary
The purpose of this study is to assess if the use of Envarsus in place of Tacrolimus-immediate release (IR) in rapid metabolizers post kidney transplant will reduce incidence of BK infection. Efficacy evaluations will include measurement of urine and serum BK values at specified time points and review of any biopsy for BK virus nephropathy. Incidence of rejection, graft failure, and graft dysfunction will also be measured at specified time points.
Interventions
- DRUG Control Group
- DRUG Study Group
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2019-05-09 |
| Est. Completion | 2022-03-16 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03762473
The ClinicalTrials.gov registry entry for NCT03762473 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Control Group is the first listed.
NCT03762473 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03762473 about?
NCT03762473 is a clinical study titled "Conversion to Envarsus Post Kidney Transplant Protects Against BK Infection". The purpose of this study is to assess if the use of Envarsus in place of Tacrolimus-immediate release (IR) in rapid metabolizers post kidney transplant will reduce incidence of BK infection. Efficacy evaluations will include measurement of urine and serum BK values at specified time points and revi...
What is the current status of trial NCT03762473?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2019-05-09. Estimated completion is 2022-03-16.
What interventions are being tested in trial NCT03762473?
The interventions under investigation include: Control Group (DRUG), Study Group (DRUG).
Who is sponsoring clinical trial NCT03762473?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.